Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?
Despite Intellia's severe stock drop from its 2021 peak, Cathie Wood is buying big.
While Cathie Wood’s involvement adds visibility, market sentiment remains mixed on whether ALMR offers sustainable upside at current valuation levels.
Wood trimmed stakes in Nvidia, Meta, and Tesla; instead, she added this speculative biotech play.
Cathie Wood recently added to her position in CRISPR Therapeutics stock.
Cathie Woods’s ARK Invest deploys $19 million across five growth stocks in this uncertain market.
Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.
Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?
These two companies fit the type of transformative growth story Cathie Wood seeks out.
This dip in Illumina’s stock could be an attractive opportunity for long-term growth investors.